These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 4930211)
1. Treatment of myelomatosis--M.R.C. trial. Galton DA Br Med J; 1971 May; 2(5757):323-4. PubMed ID: 4930211 [No Abstract] [Full Text] [Related]
2. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. Rivers SL; Patno ME JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565 [No Abstract] [Full Text] [Related]
3. Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a Medical Research Council working party. Hobbs JR Br J Haematol; 1969 Jun; 16(6):599-606. PubMed ID: 4184690 [No Abstract] [Full Text] [Related]
4. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance. Br J Haematol; 1973 Jan; 24(1):123-39. PubMed ID: 4805842 [No Abstract] [Full Text] [Related]
5. [Comparative study of the melphalan and of the cyclophosphamide in the treatment of Kahler's disease]. Bontoux D; Chenbit D; Delbarre F Therapeutique; 1971 Jan; 47(1):27-32. PubMed ID: 5572915 [No Abstract] [Full Text] [Related]
6. Multiple myeloma without initial paraproteins. Kim I; Harley JB; Weksler B Am J Med Sci; 1972 Oct; 264(4):267-75. PubMed ID: 4630526 [No Abstract] [Full Text] [Related]
8. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Carbone PP; Kellerhouse LE; Gehan EA Am J Med; 1967 Jun; 42(6):937-48. PubMed ID: 6027163 [No Abstract] [Full Text] [Related]
10. [Myeloma : symptoms, diagnosis, treatment]. Piguet H; Borg JY; Monconduit M; Bizet M Rev Prat; 1979 Jan; 29(3):333-6, 339-44, 347-8. PubMed ID: 419356 [No Abstract] [Full Text] [Related]
11. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults. Buckman R; Cuzick J; Galton DA Br J Haematol; 1982 Dec; 52(4):589-99. PubMed ID: 6958312 [TBL] [Abstract][Full Text] [Related]
17. [Visceral calcinosis induced by intravenous phosphate perfusions in myelomatous hypercalcemia]. Deshayes P; Levillain D; Cauvin M; Forthomme J Sem Hop; 1969 Feb; 45(7):444-9. PubMed ID: 4307115 [No Abstract] [Full Text] [Related]
18. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients. Matzner Y; Benbassat J; Polliack A Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296 [No Abstract] [Full Text] [Related]
19. Prognosis of myelomatosis on treatment with prednisone and cytostatics. Hansen OP; Jessen B; Videbaek A Scand J Haematol; 1973; 10(4):282-90. PubMed ID: 4764610 [No Abstract] [Full Text] [Related]
20. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Bergsagel DE; Cowan DH; Hasselback R Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]